Glaxosmithkline Share News (GSK)

London close: Stocks pull back from five-month high

- Miners, banks weigh on Footsie - Money-market rates spike in China - RSA up on bid speculation techMARK 2,624.47 -0.41% FTSE 100 6,674.48 -0.32% FTSE 250 15,494.97 -0.11% The FTSE 100 finished in negative territory for the first time in 10 trading sessions on Wednesday as traders took profits af

FTSE 100 movers: RSA rises amid heavy volume on bid talk

Chip designer ARM Holdings fell for the second straight day as investors gave a cool reaction to its third-quarter results. JPMorgan Cazenove said this morning that it sees "no reason to be building positions at this time and would take profits in the short term". A number of stocks were also trad

UPDATE: GlaxoSmithKline Hit By Ongoing Investigations In China

GSK beats Q3 earnings expectations despite missing on revenues

- Earnings ahead, revenues down - Strong cost control boosts results - GSK benefits on sale of Lucozade and Ribena GlaxoSmithKline beat earnings growth expectations in the third quarter by cutting back office and drug research and development costs were amplified by a lower tax rate. With turnove

UPDATE 1-Bribery scandal slashes GlaxoSmithKline's Chinese drug sales

* China sales slump 61 percent as doctors shun GSK products * Too early to quantify long-term impact of corruption probe * Worldwide Q3 sales 6.51 bln pounds vs consensus 6.65 bln * Q3 core EPS 28.9p vs 27.2p, helped by cost controls By Ben Hirschler LONDON, Oct 23 (

GlaxoSmithKline Hit By Ongoing Investigations In China

EU mergers and takeovers (Oct 23)

BRUSSELS, Oct 23 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process: APPROVALS AND WITHDRAWALS -- U.S. group Koch Industries to acquire electronic components maker Molex (approved Oct. 23) NEW LISTINGS -

London midday: Markets pull back from five-month high as banks fall

Concerns over the Chinese economy and a weak performance by banking stocks halted a nine-day winning streak for UK markets on Wednesday, as investors chose to take profits following a strong run. The FTSE 100 snapped a nine-day winning streak this morning, pulling back from Tuesday's finish of 6,69

Bribery scandal slashes GlaxoSmithKline's Chinese drug sales

LONDON, Oct 23 (Reuters) - GlaxoSmithKline's drug sales in China tumbled 61 percent in the third quarter, hit by a bribery scandal that has damaged its ability to market medicines in the country. Worldwide, GSK's sales were flat at 6.51 billion pounds ($10.6 billion), generating core earnin

MARKET COMMENT: UK Stocks Set For Lower Open As "China Spoils The Party"

Glaxo Venture Submits US Application for Three-Drug HIV Pill

U.S. FDA approves Actelion's lung disease drug Opsumit

Oct 18 (Reuters) - Actelion Ltd has won U.S. approval for its drug Opsumit, a successor to its pulmonary arterial hypertension drug Tracleer, which loses patent protection in 2015. Pulmonary arterial hypertension, or PAH, is characterized by high blood pressure in the arteries connecting th

MARKET PULSE- Goldman Sachs, IBM, Peabody, Winnebago, Portola Pharma

(For more market insights, including options activity, click on ; for the Day Ahead newsletter http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s) Wall Street opened lower on Thursday as investors turned their focus to the earnings of heav

MARKET PULSE- Goldman Sachs, IBM, Peabody, Verizon, SuperValu

(For more market insights, including options activity, click on ; for the Day Ahead newsletter http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s) U.S. stock index futures fell Thursday as investors digested a deal agreed by lawmakers in W

MARKET PULSE- IBM, SuperValu, Goldman Sachs, Verizon, gold stocks

(For more market insights, including options activity, click on ; for the Day Ahead newsletter http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s) U.S. stock index futures were mixed on Thursday as investors digested a deal in Washington t